---
schema_version: "secwatch.filing_event.v1"
accession: "0001933414-24-000002"
form_type: "8-K"
ticker: "MLYS"
cik: "0001933414"
company_name: "Mineralys Therapeutics, Inc."
filed_at: "2024-01-04T23:59:59+00:00"
generated_at: "2026-06-07T04:18:01.416751+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Mineralys Therapeutics appoints Minji Kim Ph.D. as CBO; splits CFO/CBO roles

## Summary
- Adam Levy remains CFO and Secretary; no longer serves as CBO as of Jan 4, 2024.
- Dr. Kim brings >20 years biotech BD experience including Jounce Therapeutics and Curis.
- Company expects clinical milestones for hypertension drug lorundrostat over next 12–18 months.
- Role split supports expanded operations as Mineralys advances late-stage development.

## SEC filing metadata
- accession: 0001933414-24-000002
- form_type: 8-K
- ticker: MLYS
- cik: 0001933414
- company_name: Mineralys Therapeutics, Inc.
- filed_at: 2024-01-04T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1933414/000193341424000002/0001933414-24-000002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1933414/000193341424000002/mlys-20240104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001933414-24-000002
- JSON: https://secwatch.observer/filing/0001933414-24-000002.json
- Plain text: https://secwatch.observer/filing/0001933414-24-000002.txt

## Key facts
- Executive change
  Adam Levy changed role as Chief Business Officer at Mineralys Therapeutics, Inc..
  - Action: no longer serves as
  - Role: Chief Business Officer
  source text: As a result, effective January 4, 2024, Adam Levy no longer serves as the Company’s Chief Business Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1933414/000193341424000002/0001933414-24-000002-index.htm
- Executive change
  Minji Kim was appointed as Chief Business Officer at Mineralys Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Business Officer
  source text: On January 4, 2024, in connection with the appointment of Minji Kim, Ph.D., as Chief Business Officer, the Board of Directors of Mineralys Therapeutics, Inc. (the “Company”) approved splitting the functions of Chief Financial Officer and Chief Business Officer into two roles.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1933414/000193341424000002/0001933414-24-000002-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.